heart attack stroke
Conditions
Interventions
Acute cardiovascular event
Atherosclerosis
Inflammation
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients with acute myocardial infarction: - 50 years or older - acute myocardial infarction (AMI) within 10 days prior to baseline measurements - clinically stable and able to undergo a PET/CT scan;Patients with ischemic stroke: - 50 years or older - Ischemic stroke within 10 days prior to baseline measurements - Clinically stable and able to undergo a PET/CT scan;Matched controls: - 50 years or older - clinically no evident (CV) disease and able to undergo a PET/CT scan
Exclusion criteria
Exclusion criteria: - Known systemic disorder such as hepatic, renal, hematologic, and malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator - Participation in a scientific study with radiation exposure in the year prior to inclusion - Planned radiation exposure in the next year due to participation in a research project with radiation exposure - Recent (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are difference in 18F-DPA-714 or signal on PET/CT in culprit (infarcted region of the heart or cerebrum) and non-culprit lesions (non-infarcted regions of the heart or cerebrum, peripheral atherosclerotic lesions), as well in the spleen and bone marrow between patients with an acute cardiovascular event versus matched controls. Furthermore, the change in 18F-DPA-714 on PET/CT within the group with an acute cardiovascular event between the acute phase and after 3 months will be determined. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secundary study parameters are difference in monocyte and circulating progenitor cell subtypes and extracellular markers between the AMI and stable patients and the change monocyte and circulating progenitor cell subtypes and extracellular markers within the AMI patients in the acute phase, after 3 months and after six months. Furthermore, the difference between the pet signal of the tracers DPA-714 will be measured. | — |
Countries
The Netherlands
Outcome results
None listed